Chapter 3 │ Page 109 34. Lin, A., et al., Oxidation of Innate Immune Checkpoint CD47 on Cancer Cells with Non-Thermal Plasma. 2021. 13(3): p. 579. 35. Lin, A., et al., Acquired non-thermal plasma resistance mediates a shift towards aerobic glycolysis and ferroptotic cell death in melanoma. Drug Resistance Updates, 2023. 67: p. 100914. 36. Heirman, P., et al., E ect of plasma-induced oxidation on NK cell immune checkpoint ligands: A computational-experimental approach. Redox Biology, 2024. 77: p. 103381. 37. Verswyvel, H., et al., Phototoxicity and cell passage a ect intracellular reactive oxygen species levels and sensitivity towards non-thermal plasma treatment in fluorescently-labeled cancer cells. Journal of Physics D: Applied Physics, 2023. 56(29): p. 294001. 38. Driehuis, E., K. Kretzschmar, and H. Clevers, Establishment of patient-derived cancer organoids for drug-screening applications. Nature Protocols, 2020. 15(10): p. 33803409. 39. Humeau, J., et al., Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models. Methods Mol Biol, 2019. 1884: p. 297-315. 40. Tatsuno, K., et al., Detection of Immunogenic Cell Death in Tumor Vaccination Mouse Model. Methods Mol Biol, 2021. 2255: p. 171-186. 41. Shirmanova, M.V., et al., Chemotherapy with cisplatin: insights into intracellular pH and metabolic landscape of cancer cells in vitro and in vivo. Scientific Reports, 2017. 7(1): p. 8911. 42. Ianevski, A., A.K. Giri, and T. Aittokallio, SynergyFinder 2.0: visual analytics of multidrug combination synergies. Nucleic Acids Res, 2020. 48(W1): p. W488-w493. 43. Bezu, L., et al., Combinatorial strategies for the induction of immunogenic cell death. Front Immunol, 2015. 6: p. 187. 44. Park, S.-J., et al., Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Oral Oncology, 2019. 95: p. 127-135. 45. Yi, M., et al., Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduction and Targeted Therapy, 2024. 9(1): p. 176. 46. Schiavoni, G., F. Mattei, and L. Gabriele, Type I Interferons as Stimulators of DCMediated Cross-Priming: Impact on Anti-Tumor Response. Front Immunol, 2013. 4: p. 483. 47. Müller, L., P. Aigner, and D. Stoiber, Type I Interferons and Natural Killer Cell Regulation in Cancer. Front Immunol, 2017. 8: p. 304. 48. Hassouneh, Z., et al., The Laws of Attraction: Chemokines as Critical Mediators in Cancer Progression and Immunotherapy Response in Bladder Cancer. Cancers, 2024. 16(19): p. 3303. 49. Muijlwijk, T., et al., Secretome and immune cell attraction analysis of head and neck cancers. Cancer Immunology, Immunotherapy, 2024. 73(11): p. 229. 50. Jung, H. and S. Paust, Chemokines in the tumor microenvironment: implications for lung cancer and immunotherapy. Front Immunol, 2024. 15: p. 1443366. 51. Kapałczyńska, M., et al., 2D and 3D cell cultures - a comparison of di erent types of cancer cell cultures. Arch Med Sci, 2018. 14(4): p. 910-919. 52. Arutyunyan, I., et al., In Vitro Models of Head and Neck Cancer: From Primitive to Most Advanced. J Pers Med, 2023. 13(11).
RkJQdWJsaXNoZXIy MTk4NDMw